Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Operating Expenses (2016 - 2025)

Historic Operating Expenses for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $1.3 million.

  • NovaBay Pharmaceuticals' Operating Expenses fell 2378.16% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 2495.08%. This contributed to the annual value of $12.3 million for FY2024, which is 2095.03% up from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Operating Expenses stood at $1.3 million for Q3 2025, which was down 2378.16% from $6.7 million recorded in Q4 2024.
  • In the past 5 years, NovaBay Pharmaceuticals' Operating Expenses registered a high of $11.2 million during Q4 2022, and its lowest value of $1.3 million during Q3 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' median Operating Expenses value was $2.9 million (recorded in 2023), while the average stood at $3.8 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 8129.86% in 2023, then surged by 22085.13% in 2024.
  • NovaBay Pharmaceuticals' Operating Expenses (Quarter) stood at $4.9 million in 2021, then surged by 129.5% to $11.2 million in 2022, then plummeted by 81.3% to $2.1 million in 2023, then skyrocketed by 220.85% to $6.7 million in 2024, then plummeted by 80.65% to $1.3 million in 2025.
  • Its Operating Expenses was $1.3 million in Q3 2025, compared to $6.7 million in Q4 2024 and $1.7 million in Q3 2024.